

1 **Markers of systemic iron status show sex-specific differences in peripheral artery**  
2 **disease: a cross-sectional analysis of HEIST-DiC and NHANES participants**

3  
4

5 **Anand Ruban Agarvas<sup>1</sup>, Stefan Kopf<sup>2,3</sup>, Paul Thalmann<sup>4</sup>, José Manuel Fernández-**  
6 **Real<sup>5</sup>, Peter Nawroth<sup>2,3</sup>, \*Martina U. Muckenthaler<sup>1,6,7,8</sup>**

7

8 **Affiliations**

9 <sup>1</sup>Center For Translational Biomedical Iron Research, Department of Pediatric Hematology,  
10 Oncology Immunology and Pulmonology, University Hospital Heidelberg, Heidelberg,  
11 Germany.

12 <sup>2</sup>Clinic for Endocrinology, Diabetology, Metabolic Diseases and Clinical Chemistry (Internal  
13 Medicine 1), Heidelberg University Hospital, Heidelberg, Germany.

14 <sup>3</sup>German Center of Diabetes Research (DZD), Neuherberg, Germany.

15 <sup>4</sup>Institute of Medical Biometry, University Hospital Heidelberg, Heidelberg, Germany.

16 <sup>5</sup>Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de  
17 Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona  
18 17007, Spain.

19 <sup>6</sup>Molecular Medicine Partnership Unit, Heidelberg, Germany.

20 <sup>7</sup>Translational Lung Research Center Heidelberg (TLRC), German Center for Lung  
21 Research (DZL), University of Heidelberg, Heidelberg, Germany.

22 <sup>8</sup>German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim,  
23 Germany.

24

25 *\*Corresponding author*

26

27

28 **Address for correspondence**

29 Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg,  
30 Heidelberg, Germany.

31 Tel.: +496221566923; Fax: +496221564580. E-mail: [martina.muckenthaler@med.uni-](mailto:martina.muckenthaler@med.uni-heidelberg.de)  
32 [heidelberg.de](mailto:martina.muckenthaler@med.uni-heidelberg.de) (M.U. Muckenthaler).

33 **Abstract**

34

35 **Background**

36 Iron has been proposed as a risk factor for atherosclerosis but the data are controversial.  
37 We previously showed that non-transferrin-bound iron (a fraction of iron appearing in iron  
38 overload) contributes to atherosclerosis. Here, we investigated whether iron within  
39 physiological limits influenced atherosclerosis by studying its association with vascular  
40 dysfunction and peripheral arterial disease (PAD). Further, we evaluated if this relationship  
41 was influenced by comorbidities.

42

43 **Methods**

44 We studied the association between iron biomarkers in blood and markers for vascular  
45 adhesion and PAD in 368 individuals registered in the Heidelberg Study on Diabetes and  
46 Complications (HEIST-DiC). Our observations were validated by analyzing the association  
47 between iron biomarkers and PAD in the National Health and Nutrition Examination Survey  
48 (NHANES 1999-2004) data.

49

50 **Results**

51 In both HEIST-DiC and NHANES cohorts, plasma ferritin levels are positively associated  
52 with PAD in females and not in males. We further identified negative associations between  
53 TIBC and plasma iron levels with PAD among females. These relationships were  
54 independent of the presence of other comorbidities including hypertension, insulin  
55 resistance, prediabetes, and diabetes.

56 **Conclusion**

57 We demonstrate a sex-specific alteration of markers of systemic iron availability in  
58 individuals with clinically apparent PAD implying that mechanisms of disease development  
59 may differ between males and females. Elevated ferritin levels and hypoferrremia in females  
60 are indicative of an underlying inflammation that may affect the pathogenesis of PAD. The  
61 observed lack of a positive association of PAD with serum iron levels suggest that  
62 “physiological” iron concentrations are safe for vascular health.

63

64 **Keywords**

65 Iron, Vascular Diseases, Arterial Occlusive Diseases, Atherosclerosis, Peripheral Arterial  
66 Disease

67 **Introduction**

68 Peripheral arterial disease (PAD) is a common atherosclerotic vascular disorder of the  
69 arteries of the lower limbs and affects millions of individuals worldwide<sup>1,2</sup>. Unrecognized and  
70 untreated PAD reduces blood flow to the lower extremities resulting in leg pain, impaired  
71 mobility, and amputation. Moreover, it is associated with an increased risk of cardiovascular  
72 morbidity and mortality<sup>3</sup>. Compared to cardiovascular and cerebrovascular disease, PAD is  
73 less well studied, and our understanding of the disease process is still poor. Among the  
74 known risk factors of PAD include old age, smoking, and comorbidities such as diabetes and  
75 hypertension<sup>1</sup>. A recent genome-wide association study<sup>4</sup> identified genetic loci that are  
76 unique to PAD, in addition to those shared between the different atherosclerotic disorders  
77 (coronary, cerebral, and peripheral) suggesting that additional mechanisms may contribute  
78 to the pathophysiology of PAD.

79

80 Iron is an essential micronutrient and its homeostasis is controlled by regulatory systems  
81 that maintain its absorption, transport, and storage<sup>5</sup>. If iron accumulates in excess, it  
82 contributes to the generation of reactive oxygen species. Iron is, therefore, discussed as a  
83 risk factor for the development of atherosclerosis and cardiovascular disease<sup>6</sup>. We  
84 previously analysed mouse models and humans with iron overload disorder,  
85 hemochromatosis, and found that excess iron played a multifaceted role in atherosclerosis  
86 depending on the compartment where it is localized<sup>7</sup>. Under physiological conditions, iron is  
87 bound to transferrin in the plasma, and is transported to those cells that require iron. Iron  
88 occupies only one-third of transferrin's binding sites, therefore, free iron can be sequestered  
89 in the circulation. However, in pathological states associated with iron overload, most binding  
90 sites on transferrin are saturated resulting in the appearance of 'non-transferrin-bound iron  
91 (NTBI)'. We found that NTBI in circulation contributes to atherosclerosis by oxidising low-  
92 density lipoproteins (LDL) and inducing vascular dysfunction<sup>7</sup>. In addition, iron deposition in  
93 the vasculature of hemochromatotic mice was associated with enhanced atherosclerosis<sup>7</sup>.  
94 An interesting open question is whether iron levels within physiological limits influence  
95 atherogenesis. The available data is controversial.

96

97 The relationship between iron and atherosclerosis has been commonly studied by analyzing  
98 the association of one or more iron biomarkers [e.g. plasma iron, ferritin, transferrin,  
99 transferrin saturation (TSAT)] with atherosclerosis markers (e.g. coronary artery calcium or  
100 carotid intima-media thickness)<sup>8-14</sup>. On the other hand, studies have also been performed  
101 that consider blood donation as an iron-depletion strategy and evaluated atherosclerosis risk  
102 in blood donors<sup>15-19</sup>. More recently, Gill *et al.* used a Mendelian randomization approach to

103 evaluate the risk of venous thromboembolism and carotid atherosclerosis with the  
104 genetically determined iron status<sup>14</sup>.

105

106 The relationship between iron and PAD is less well-studied. Menke *et al.* showed that ferritin  
107 and TSAT are positively associated with PAD in the National Health and Nutrition  
108 Examination Survey 1999-2002 (NHANES), especially among participants with elevated  
109 cholesterol<sup>20</sup>. Among individuals on hemodialysis, one study found that PAD was associated  
110 with anemia and low iron levels<sup>21</sup> while the other found a positive association with ferritin  
111 levels<sup>22</sup>. Results of a randomized controlled trial suggested that among participants with  
112 established PAD, the iron reduction did not improve the clinical outcomes or mortality<sup>23</sup>.  
113 Several open questions remain: Are there differences in how iron parameters influence  
114 atherosclerosis at different sites? Do iron biomarkers correlate with the severity of PAD? If  
115 so, how? How are these relationships influenced by sex or the presence of prediabetes or  
116 diabetes?

117

118 Here we analyzed iron biomarkers within physiological limits for association with markers for  
119 vascular function and PAD in a cohort of individuals with diabetes and prediabetes enrolled  
120 in the Heidelberg Study on Diabetes and Complications (HEIST-DiC). We validated our  
121 observations by analyzing the NHANES 1999-2004 data.

122

## 123 **Methods**

### 124 **Participants**

#### 125 ***HEIST-DiC study***

126 We retrospectively analysed the data from 368 individuals enrolled in the HEIST-DiC study  
127 (Clinical trials.gov NCT03022721). The selection criteria for participants have been  
128 described previously<sup>24</sup>; in addition, we excluded those with values of serum iron biomarkers  
129 suggestive of likely hemochromatosis<sup>25</sup>. For all participants, a detailed medical history was  
130 obtained. The ankle-brachial index (ABI) was measured using noninvasive blood pressure  
131 measurements of arms and ankles (ABI System 1000; Boso d.o.o.). Blood samples were  
132 obtained in the fasting state and all baseline parameters were analyzed under standardized  
133 conditions in the central laboratory of the University Hospital of Heidelberg. Serum samples  
134 were stored at -80C until further analysis. We used iron, ferritin, and TSAT were used as  
135 biomarkers of systemic iron status and serum intercellular adhesion molecule-1 (ICAM1) and  
136 vascular-cell adhesion molecule-1 (VCAM1) were used as markers of vascular dysfunction.  
137 We measured ICAM1 (#171B6009M) and VCAM1 (#171B6022M) using multiplex magnetic  
138 bead-array-based technology on a BioPlex200 system (Bio-Rad) according to the  
139 manufacturer's instructions. All participants provided written informed consent and the ethics

140 committees of the University of Heidelberg approved this study (Decision No. 204/2004,  
141 400/2010, and S-383/2016) according to the Declaration of Helsinki.

## 142 **NHANES**

143 NHANES is designed to assess the health and nutritional status of adults and children in the  
144 United States. The survey includes both an interview component, in which participants are  
145 asked questions about their health and lifestyle, and a physical examination component, in  
146 which various measurements and samples are collected. We obtained data from 15969  
147 participants over 40 years in 3 consecutive cycles of NHANES (1999-2004) for whom ABI  
148 was measured. We applied the following exclusion criteria: not even one ABI measurement  
149 available, likely hemochromatosis<sup>25</sup>, anemia (hemoglobin <10g/L), on current hormonal  
150 medications or iron supplements, cancer, donated blood in the last 1 month, with features of  
151 kidney disease (on dialysis or severe albuminuria), pregnant or breastfeeding in the last  
152 year, high risk of liver fibrosis, concurrent inflammation [C-Reactive Protein (CRP) >3μg/L]  
153 and with a feature of familial hyperlipidemia [LDL-Cholesterol (LDLc) >4.9mM]. This resulted  
154 in a final sample number of 9336 participants. We obtained data from the following iron  
155 biomarkers from NHANES: iron, ferritin, total iron binding capacity (TIBC), and TSAT.

156

157 Among the demographic variables, age (in years) and body mass index (BMI) were obtained  
158 and used as is from NHANES. Smoking and alcohol were categorized according to a  
159 previous study<sup>26</sup>. We categorized diabetes based on self-reported history, current use of  
160 insulin or oral hypoglycemic agents, fasting plasma glucose (FPG) ≥7.0 mM, or glycated  
161 hemoglobin (HbA1c) ≥6.5%. Prediabetes was defined among those with an absent self-  
162 reported history of diabetes and one of the following: FPG 5.6-6.9 mM or HbA1c 5.7-6.4%.  
163 We categorized hypertension based on self-reported history or current use of anti-  
164 hypertensive agents or systolic blood pressure >130 mmHg or diastolic blood pressure >80  
165 mmHg. The presence of nonalcoholic fatty liver disease (NAFLD) was categorized by  
166 calculating FIB-4 score<sup>27</sup>. Assays for the analytes in NHANES were performed under strict  
167 laboratory protocols (for more details on data fields and procedure manuals, see  
168 Supplementary Table 2). As an index of insulin resistance, we calculated HOMA2-IR using  
169 C-peptide values instead of insulin<sup>28</sup>.

170

## 171 *Categorization as PAD*

172 In both cohorts, ABI values were measured on both the right and left limbs. We categorized  
173 PAD when the ABI value on one of the sides was <0.9 or >1.4 as per recommendations<sup>29</sup>.

174

## 175 **Statistical analysis**

176 For the analysis of participants in both cohorts, the following aspects were similar: we  
177 modelled the probability of PAD's presence with one of the iron biomarkers (iron, ferritin, or  
178 TSAT) by logistic regression using a nested approach. Since iron metabolism shows sex-  
179 specific differences, we conducted a sex-stratified analysis. In general, we included variables  
180 that are known to affect iron homeostasis or the risk of PAD as covariates. Further, all  
181 continuous variables were mean-centered for the analysis, and variables were included in  
182 the models only when their missing data was <10%.

183

184 Some study-specific aspects of the analysis are described below. For the HEIST-DiC study,  
185 we built 3 different regression models that analysed the association between iron biomarkers  
186 and PAD or markers of vascular dysfunction (ICAM1, VCAM1). Model 1 was univariate.  
187 Model 2 was built on model 1 by adjusting for demographic variables: sex (males as  
188 reference), presence of diabetes, and hypertension (absence of disease as reference).  
189 Model 3 was built on Model 2 by including additional covariates [high sensitivity CRP  
190 (hsCRP), LDLc, HbA1c, and urine albumin creatinine ratio (ACR); all continuous]. As  
191 subgroup analysis in the HEIST-DiC cohort, we conducted univariate regression for iron  
192 parameters only in individuals with diabetes; we did not conduct a subgroup analysis for  
193 prediabetes since the number of patients with PAD in this group was small (2/23).

194

195 For the NHANES data, only the association between iron biomarkers and PAD was  
196 analyzed. Model 1 represents the univariate analysis, while models 2-4 are multivariate.  
197 Model 2 was built on model 1 by adjusting for demographic variables (age, BMI, smoking  
198 (non-smokers as reference), and ethnicity (non-Hispanic whites as the reference). Model 3  
199 was built on model 2 by incorporating the following covariates (as categorical: the presence  
200 of diabetes, and hypertension (absence of disease as reference), FIB4 score [<1.2 as  
201 reference]; as continuous: CRP, ACR. Model 4 was built on model 3 by including HOMA2-  
202 IR, LDLc, use of antihyperlipidemic and antiplatelet agents (the former two variables as  
203 continuous and the latter two as categorical). For the NHANES dataset, we also conducted a  
204 sensitivity analysis by conducting the analyses on the whole cohort without the exclusion of  
205 data. In addition, sample weights were included all the analyses.

206

207 A p-value<0.05 was considered statistically significant. All statistical analyses and  
208 visualizations were performed using R Statistical Software (v4.2.2<sup>30</sup>). Reporting of the study  
209 is as per The Strengthening the Reporting of Observational Studies in Epidemiology  
210 (STROBE) guidelines<sup>31</sup>. We have also developed a data exploration tool for readers to  
211 explore the datasets and interactively create their visualizations from the paper  
212 ([https://anandr.shinyapps.io/NHANES\\_HEISTDiC/](https://anandr.shinyapps.io/NHANES_HEISTDiC/)) using Quarto<sup>32</sup> and Shiny<sup>33</sup>.

213

## 214 **Results**

### 215 ***HEIST-DiC study***

216 The HEIST-DiC is a prospective, observational study designed to analyze the development of  
217 complications in individuals with diabetes and prediabetes. We investigated the relationship  
218 between systemic iron biomarkers and PAD in the baseline data and the participant  
219 characteristics are shown in Table 1. The overall prevalence of PAD was 6.6% with a higher  
220 proportion among males (17/192) than females (6/165). Among both sexes, the participants  
221 with PAD were older and a majority of them also had associated diabetes and hypertension;  
222 the proportion of individuals with prediabetes and PAD was small (Table 1). Vascular  
223 adhesion markers such as ICAM1 and VCAM1 were significantly higher only among the  
224 males with PAD (Table 1). Among the iron biomarkers, ferritin was elevated among females  
225 with PAD while iron, transferrin, and TSAT were not significantly different. Of note, significant  
226 differences between iron parameters and PAD were not noted in males.

227

228 In the regression analyses, ferritin was associated with an increased probability of PAD in  
229 females but not males (Figure 1). This positive association was significant in models 1 and 2  
230 (Model 1: OR 3.23, 95% CI 1.23-8.7, P=0.013, Model 2: OR 2.87, 95% CI 0.96-9.18,  
231 P=0.06) however, an increased risk was also evident in the Model 3 (OR 1.86, 95% CI 0.38-  
232 8.1, P=0.4). The positive association of ferritin with PAD persisted in models adjusted for the  
233 comorbidities diabetes and hypertension (Model 2 and Model 3); further, ferritin also showed  
234 a tendency for a positive association in the diabetes subgroup (OR 2.44, 95% CI 0.8-7.14,  
235 P=0.09). On the other hand, iron and TSAT did not show a significant association with PAD  
236 in either sex (Figure 1). In contrast to our previous observations in individuals with  
237 hemochromatosis<sup>7</sup>, markers of vascular dysfunction such as ICAM1 and VCAM1 were not  
238 significantly associated with iron parameters within physiological ranges (iron, ferritin, or  
239 TSAT) in both sexes (Figures 2-3).

240

### 241 ***NHANES***

242 This part of the study builds upon a previous analysis of the NHANES 1999-2002 cycles by  
243 Menke *et al.*<sup>20</sup> by including data from the NHANES 2003-2004 cycle. The baseline  
244 characteristics of the NHANES 1999-2004 participants included in the study are shown in  
245 Table 2. Overall, the prevalence of PAD in the population was 6.25% with a significantly  
246 higher prevalence among females (males: 4.96%, females: 7.9%; p=0.001). Among  
247 individuals with PAD, we observed differences in ethnicity, sex, presence of diabetes,  
248 smoking, alcohol status, physical activity, and use of antihyperlipidemic and antiplatelet  
249 medications (Table 2). The prevalence of PAD increased with older age (median: 69 for

250 males,  $P < 0.001$ ; 71 for females,  $P < 0.001$ ) with a higher percentage from the non-Hispanic  
251 white ethnicity (84% for males,  $P = 0.003$ ; 78% for females,  $P = 0.005$ ). BMI was significantly  
252 higher among females with PAD while it was not different for males (median: 28 for males,  $P$   
253  $= 0.8$ ; 29 for females,  $P = 0.014$ ). The proportion of alcohol drinkers was comparable for both  
254 sexes and was not statistically different (5.2% for males,  $P = 0.6$ ; 6% for females,  $P > 0.9$ ).

255

256 Among both sexes, the proportion of PAD participants with prediabetes (2.4% for males;  
257 2.7% for females) or diabetes (2.3% for males; 3.0% for females) were comparable. The  
258 overall prevalence of hypertension was higher among those with PAD (9.9% of males,  
259  $p = 0.003$ ; and 11.8% of females,  $p = 0.6$ ). Smoking status was different among the sexes in  
260 the PAD group: among males, the proportion of former and current smokers was significantly  
261 higher (Non-smokers 1.7%, Former smokers 4.2%, Current smokers 2.3%;  $P < 0.001$ ) while  
262 the distribution was not different among females (Non-smokers 5.4%, Former smokers 3.1%,  
263 Current smokers 1.8%;  $P = 0.2$ ). As expected, lower physical activity was also associated with  
264 PAD in both sexes (50% of males and 57% of females). Among both sexes, the PAD  
265 subgroup also had a higher FIB4 score indicating a greater degree of liver fibrosis (Males:  
266 1.35,  $P < 0.001$ ; Females: 1.14  $P < 0.001$ ).

267

268 Among the iron biomarkers, serum iron (Median 80, IQR 64-108  $\mu\text{g/dL}$ ;  $P < 0.001$ ) and  
269 transferrin saturation (Median 24, IQR 17-30;  $P = 0.021$ ) were lower in males with PAD while  
270 females with PAD showed higher ferritin (Median 87, IQR 56-252  $\text{ng/mL}$ ;  $P < 0.001$ ) and  
271 lower TIBC (Median 60, IQR 54-68;  $P < 0.001$ ). Marginal differences were also observed in  
272 some laboratory parameters within both sexes with PAD (e.g. albumin, AST, urea,  
273 creatinine, C-reactive protein, and albumin-creatinine ratio; Table 2).

274

275 Consistent with our observations in the HEIST-DiC cohort, serum ferritin levels showed a  
276 positive association with PAD only in females (Figure 4). This positive association was  
277 strongest in Model 4, the most complex regression model we built (OR 3.6, 95% CI 1.25-  
278 10.6,  $P = 0.018$ ). Interestingly, TIBC analysis showed a significant negative association with  
279 PAD only among females (OR 0.71, 95% CI 0.58-0.88,  $P = 0.002$ ; Model 2: OR 0.63, 95% CI  
280 0.5-0.79,  $P < 0.001$ ; Model 3: OR 0.56, 95% CI 0.41-0.75,  $P < 0.001$ ; Model 4: OR 0.29, 95%  
281 CI 0.12-0.7,  $P = 0.006$ ; Figure 4). By contrast, none of the associations for ferritin and TIBC  
282 were significant for males. On the other hand, serum iron levels (Figure 4), were negatively  
283 associated with PAD in both females (Model 1: OR 0.75, 95% CI 0.61-0.92,  $P = 0.005$ ; Model  
284 2: OR 0.77, 95% CI 0.61-0.98,  $P = 0.034$ ; Figure 4) and males (Model 1: OR 0.79, 95% CI  
285 0.62-1,  $P = 0.046$ ). For TSAT, a positive association for females was observed in Model 4  
286 (OR 2.87, 95% CI 1.15-6.92,  $P = 0.023$ ) while a negative association was noted for males



287 (Model 1: OR 0.75, 95% CI 0.61-0.93, P=0.008; Model 2: OR 0.8, 95% CI 0.64-0.99,  
288 P=0.041; Figure 4).

289

290 We next analysed associations of other covariates with PAD from Model 4 (Supplementary  
291 Table 1). Of note, BMI had no association with PAD, while smoking showed a positive  
292 association among both sexes that was more pronounced in males; interestingly, male  
293 former smokers showed a negative association with PAD although, a positive association  
294 still remained among females (Supplementary Table 1). Furthermore, the presence of  
295 prediabetes was positively associated with PAD among males and negatively among  
296 females; on the other hand, the presence of diabetes was negatively associated with PAD in  
297 both sexes. HOMA2-IR showed positive associations among both males and females while  
298 CRP showed a positive association mainly among females (Supplementary Table 1).

299

### 300 *Sensitivity analysis*

301 To test the robustness of the relationships, we conducted a sensitivity analysis on the whole  
302 NHANES 1999-2004 cohort without applying any exclusion criteria. Here, we found that  
303 ferritin (in Model 1) and TIBC's observations in females (Models 1-3) were robust enough to  
304 retain their significant relationships (Supplementary Figure 1).

305

### 306 **Discussion**

307 While the majority of studies undertaken so far have focused on the relationship between  
308 iron and cardiovascular disease, only a few studies have investigated the role of iron in the  
309 development of atherosclerosis: furthermore, the topic of how iron biomarkers correlate with  
310 PAD, specifically, is rarely addressed. We, therefore, analyzed the data from two patient  
311 cohorts: HEIST-DiC and NHANES. Since iron parameters show important sex-specific  
312 differences, we conducted stratified analyses for males and females and additionally  
313 analysed if prediabetes or diabetes affected the observed relationships.

314

315 There were no significant associations between iron parameters within the physiological  
316 range and markers of vascular dysfunction (ICAM1 or VCAM1), despite their elevated levels  
317 in males with PAD. However, we observed sex-specific associations of iron biomarkers with  
318 PAD, a relationship that was independent of the presence of other comorbidities including  
319 hypertension, insulin resistance, prediabetes, and diabetes (Supplementary Table 1). In  
320 both, the HEIST-DiC and NHANES patient cohorts, plasma ferritin levels are positively  
321 associated with PAD in females and not in males. The positive association for higher serum  
322 ferritin among females with PAD reported here strengthens the previous observations on the  
323 NHANES 1999-2001 cohort<sup>20</sup> and agrees with a previous study on carotid atherosclerosis<sup>34</sup>.

324 These findings are also, at least, partially consistent with studies that report ferritin's positive  
325 association with carotid/coronary atherosclerosis. These studies do not observe major sex-  
326 specific differences<sup>8,12,13</sup>. On the contrary, the lack of a predictive role for ferritin in males is  
327 in contrast to a previous study which reports a “U-shaped” relationship with cardiovascular  
328 disease among males<sup>35</sup>. The sex-specific associations of ferritin identified in the patient  
329 cohorts described here also contrast findings in two other large cohort studies: i) a Danish  
330 cohort that observed an increased risk of all-cause mortality for ferritin among both males  
331 and females<sup>36</sup> and ii) a British cohort that observed an increased risk of cardiovascular  
332 mortality among males with high ferritin and increased all-cause mortality among females  
333 with low ferritin<sup>37</sup>.

334

335 Interestingly, in the NHANES cohort, we further identified negative associations between  
336 TIBC with PAD in females but not in males. This relationship between TIBC and PAD was  
337 strong and robust, as evident from the sensitivity analysis (Figure 4; Supplementary Figure  
338 1). Our findings thus support two previous studies that have analyzed the relationship  
339 between TIBC and atherosclerosis<sup>12,38</sup>. Further, among both sexes, plasma iron showed a  
340 negative association with PAD. The following studies on plasma iron and PAD do show  
341 similar negative associations but have not investigated sex-specific differences. For  
342 example, serum iron levels were reduced in hemodialysis patients with PAD ( $9.9 \pm 3.0 \mu\text{M}$ )  
343 compared to those without PAD ( $11.5 \pm 3.3 \mu\text{M}$ ;  $p=0.004$ )<sup>21</sup>. The study by Vega De Céniga  
344 *et al.* also observed a higher prevalence of iron deficiency (31.9% with iron  $<58 \text{ mcg/dL}$ ) and  
345 anemia (49.5%) among PAD participants<sup>39</sup>.

346

347 In our analyses, the association for TSAT with PAD showed contrasting observations in  
348 males and females. While the HEIST-DiC cohort had insignificant associations for TSAT  
349 (Figure 3), the NHANES cohort showed a positive association among females in Model 4  
350 while the association was negative among males (Figure 4). Otaki *et al.* reported reduced  
351 TSAT levels in PAD in a Japanese patient cohort and also found a correlation between  
352 TSAT with the severity of PAD<sup>40</sup>. Similar negative associations with TSAT have also been  
353 made in the context of cardiovascular disease in both sexes<sup>11,12,14,41</sup>. For the interpretation of  
354 TSAT, it is also important to consider that it is a calculated measure<sup>42</sup>. While the HEIST-DiC  
355 study applied a formula including measured transferrin levels, the NHANES cohort used a  
356 formula applying TIBC. Therefore, we are cautious in interpreting the associations of TSAT  
357 in our study.

358

359 Our data extend on our previous findings, where we observed a striking correlation of NTBI  
360 and vascular dysfunction and atherosclerosis.<sup>7,43</sup> From this current study we conclude that  
361 serum iron levels within physiological limits are safe for vascular health. These findings  
362 agree with our previous proposed model<sup>7</sup> that only the labile iron fractions in the circulation  
363 (eg., NTBI) in iron-loaded states plays a pathological role. Nevertheless, the associations  
364 between iron biomarkers with PAD in females have several important implications. If ferritin  
365 were interpreted as an indicator of body iron stores, our study suggests that there is an  
366 increased risk of PAD at the upper end of, what is clinically accepted as a “physiological”  
367 iron status. This finding would directly contrast our observation on the negative relationship  
368 between PAD and iron/TIBC which implies an increased PAD risk in iron-deficient states.  
369 This could be interpreted as an “U-shaped” relationship between iron status and  
370 cardiovascular disease as noted in two previous studies investigating the NHANES  
371 cohort<sup>41,44,45</sup>. However, ferritin is also an acute phase reactant with increased expression in  
372 conditions of inflammation<sup>46</sup>. In inflammatory conditions, hypoferrremia (low iron levels in the  
373 plasma) arises from a reduced iron export via ferroportin from macrophages and duodenal  
374 enterocytes by hepcidin-controlled<sup>47</sup> and transcriptional mechanisms<sup>48,49</sup>. Consequently,  
375 iron-exporting cells such as macrophages become iron loaded contributing to elevated  
376 ferritin levels<sup>50</sup>. Overall, our findings may also suggest an iron redistribution in response to  
377 an underlying inflammation that may render individuals more susceptible to PAD. Although  
378 we excluded samples with CRP<3 mg/dL and used CRP as a covariate, the presence of  
379 microinflammation in tissues cannot be completely excluded from the available data.

380

381 We further need to interpret our findings in the context of The Iron and Atherosclerosis Study  
382 (FeAST; [www.clinicaltrials.gov](http://www.clinicaltrials.gov), Identifier NCT00032357), a major trial that investigated the  
383 benefits of iron reduction on the clinical outcomes in a cohort of individuals with PAD<sup>23</sup>.  
384 While the initial analysis of the FeAST trial results did not report a favorable outcome  
385 following phlebotomy<sup>23</sup>, the reanalysis of the results adjusting for the effects of age<sup>51</sup> and  
386 smoking<sup>52</sup> have suggested that iron reduction (with ferritin and TSAT as endpoints) could be  
387 of significant benefit for younger individuals and smokers. However, an overwhelming  
388 majority of the FeAST trial participants are males (~98%)<sup>23</sup>, therefore, sex-specific  
389 differences could not be analyzed.

390

391 Taken together, our data suggest that iron redistribution to macrophages and reduced  
392 systemic iron availability may play a role in PAD. Some of the parameters analyzed are  
393 altered in a sex-specific manner implying that mechanisms of PAD development may differ  
394 between males and females. The strength of our study lies in the analyses of two  
395 independent cohorts, allowing for a generalization of the findings, an increased robustness

396 of the data, and a reduction of cohort-specific biases. In both cohorts, we observed a similar  
397 prevalence of PAD (~6%) associated with well-known risk factors (old age, diabetes, and  
398 hypertension). The examination of multiple iron biomarkers, including serum iron, ferritin,  
399 TSAT, and TIBC provides a comprehensive analysis of the relationship between iron and  
400 clinically apparent PAD. This is also the first study to evaluate the relationship between iron  
401 biomarkers and PAD in prediabetes and diabetes.

402

403 Limitations include the cross-sectional nature of the study which limits causal inferences and  
404 precludes the assessment of temporal relationships. The HEIST-DiC cohort consisted of  
405 mainly European individuals with diabetes and prediabetes from a hospital-based study,  
406 while NHANES is a survey cohort, representative of the US population, and therefore  
407 contains a mix of ethnicities. Further, we were unable to control for all possible confounding  
408 factors, such as genetic predisposition, lifestyle, medications, or other comorbidities. The  
409 study described here also did not investigate potential mechanisms underlying the observed  
410 associations.

411

## 412 **Conclusion**

413 Overall, our findings suggest that “physiological” iron concentrations are safe for vascular  
414 health. We also find evidence of an association between systemic iron biomarkers and PAD  
415 specifically among females. Further studies are necessary to confirm whether the observed  
416 associations are indeed causal and to explore the potential mechanisms underlying this  
417 relationship. Understanding the role of iron in the development of PAD could lead to the  
418 development of new preventive and therapeutic strategies for this condition. Our findings  
419 need to be considered explorative to encourage the investigation of potential biological  
420 pathways underlying the sex-specific differences in iron’s influence on atherosclerosis.

421

## 422 **Ethics statement**

423

424 The ethics committees of the University of Heidelberg approved this study (Decision No.  
425 204/2004, 400/2010, and S-383/2016) according to the Declaration of Helsinki. All patients  
426 entered the study according to the guidelines of the local ethics committees following written  
427 informed consent to participate.

428

## 429 **Funding**

430

431 The HEIST-DiC study was funded by the Deutsche Forschungsgemeinschaft (SFB1118).  
432 MUM received funding from the DFG (SFB1118) and Translational Lung Research Center

433 Heidelberg (TLRC), German Center for Lung Research (DZL; Project No. FKZ  
434 82DZL004A1).

435

#### 436 **Author contributions**

437

438 Anand Ruban Agarvas: Conceptualization, Methodology, Software, Formal analysis,  
439 Investigation, Data curation, Writing- Original draft, Visualization

440 Stefan Kopf: Investigation, Resources, Writing - Review & Editing

441 Paul Thalmann: Validation, Writing - Review & Editing

442 José Manuel Fernández-Real: Methodology, Writing - Review & Editing, Supervision

443 Peter Nawroth: Project administration, Funding acquisition, Supervision, Writing - Review &  
444 Editing

445 Martina U. Muckenthaler: Conceptualization, Methodology, Supervision, Writing - Review &  
446 Editing, Project administration, Funding acquisition

447

448

#### 449 **Conflict of interest**

450 None to declare

451

#### 452 **Data and Code Availability Statement**

453 The data from this study can be explored here:

454 [https://anandr.shinyapps.io/NHANES\\_HEISTDiC/](https://anandr.shinyapps.io/NHANES_HEISTDiC/). The HEIST-DiC dataset analyzed in the

455 current study is available from the corresponding authors on reasonable request. The

456 NHANES dataset is publicly available. Codes used for data analysis and visualization are

457 accessible here (<https://github.com/griffindoc/pad>)

458

#### 459 **References**

460

461 1. Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease.

462 *Circ Res.* 2021;128(12):1818-1832. doi:10.1161/CIRCRESAHA.121.318535

463 2. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE,

464 Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of

465 prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review

466 and analysis. *The Lancet.* 2013;382(9901):1329-1340. doi:10.1016/S0140-6736(13)61249-0

467 3. Fowkes F, Murray G, Butcher I, Folsom A, Hirsch A, Couper D, DeBacker G, Kornitzer M,

468 Newman A, Sutton-Tyrrell K, Cushman M, Lee A, Price J, D'Agostino R, Murabito J, Norman P,

469 Masaki K, Bouter L, Heine R, Stehouwer C, McDermott M, Stoffers H, Knottnerus J, Ogren M,

470 Hedblad B, Koenig W, Meisinger C, Cauley J, Franco O, Hunink M, Hofman A, Wittteman J, Criqui

471 M, Langer R, Hiatt W, Hamman R, Ankle Brachial Index Collaboration. Development and

472 validation of an ankle brachial index risk model for the prediction of cardiovascular events. *Eur*

473 *J Prev Cardiol.* 2014;21(3):310-320. doi:10.1177/2047487313516564

- 474 4. VA Million Veteran Program, Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee  
475 KM, Shao Q, Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, Wang  
476 L, Chen J, Saleheen D, Lee JS, Miller DR, Reaven P, Alba PR, Patterson OV, DuVall SL, Boden WE,  
477 Beckman JA, Gaziano JM, Concato J, Rader DJ, Cho K, Chang KM, Wilson PWF, O'Donnell CJ,  
478 Kathiresan S, Tsao PS, Damrauer SM. Genome-wide association study of peripheral artery  
479 disease in the Million Veteran Program. *Nat Med*. 2019;25(8):1274-1279. doi:10.1038/s41591-  
480 019-0492-5
- 481 5. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. *Cell*.  
482 2017;168(3):344-361. doi:10.1016/j.cell.2016.12.034
- 483 6. Sullivan Jerome L. IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK. *The Lancet*.  
484 1981;317(8233):1293-1294. doi:10.1016/S0140-6736(81)92463-6
- 485 7. Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S,  
486 Seide SE, Sparla R, Hentze MW, Muckenthaler MU. Atherosclerosis is aggravated by iron  
487 overload and ameliorated by dietary and pharmacological iron restriction. *Eur Heart J*.  
488 Published online March 20, 2019. doi:10.1093/eurheartj/ehz112
- 489 8. Wolff B, Völzke H, Lüdemann J, Robinson D, Vogelgesang D, Staudt A, Kessler C, Dahm JB, John  
490 U, Felix SB. Association between high serum ferritin levels and carotid atherosclerosis in the  
491 study of health in Pomerania (SHIP). *Stroke*. 2004;35(2):453-457.  
492 doi:10.1161/01.STR.0000114875.31599.1C
- 493 9. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin Is Independently Associated  
494 With the Presence of Coronary Artery Calcium in 12 033 Men. *ATVB*. 2012;32(10):2525-2530.  
495 doi:10.1161/ATVBAHA.112.253088
- 496 10. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid  
497 atherosclerosis: prospective results from the Bruneck study. *Circulation*. 1997;96(10):3300-  
498 3307. doi:10.1161/01.cir.96.10.3300
- 499 11. Das De S, Krishna S, Jethwa A. Iron status and its association with coronary heart disease:  
500 systematic review and meta-analysis of prospective studies. *Atherosclerosis*. 2015;238(2):296-  
501 303. doi:10.1016/j.atherosclerosis.2014.12.018
- 502 12. Guo S, Mao X, Li X, Ouyang H. Association between iron status and incident coronary artery  
503 disease: a population based-cohort study. *Sci Rep*. 2022;12(1):17490. doi:10.1038/s41598-022-  
504 22275-0
- 505 13. Klip IJT, Voors AA, Swinkels DW, Bakker SJL, Kootstra-Ros JE, Lam CS, Van Der Harst P, Van  
506 Veldhuisen DJ, Van Der Meer P. Serum ferritin and risk for new-onset heart failure and  
507 cardiovascular events in the community: Serum ferritin and risk for new-onset HF and CV  
508 events. *Eur J Heart Fail*. 2017;19(3):348-356. doi:10.1002/ejhf.622
- 509 14. Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, INVENT  
510 Consortium, Tzoulaki I, Dehghan A. Effects of Genetically Determined Iron Status on Risk of  
511 Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization  
512 Study. *J Am Heart Assoc*. 2019;8(15):e012994. doi:10.1161/JAHA.119.012994
- 513 15. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of Blood Is Associated  
514 with Reduced Risk of Myocardial Infarction: The Kuopio Ischaemic Heart Disease Risk Factor

- 515 Study. *American Journal of Epidemiology*. 1998;148(5):445-451.  
516 doi:10.1093/oxfordjournals.aje.a009669
- 517 16. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body  
518 iron through blood donation on incident cardiac events. *Transfusion*. 2002;42(9):1135-1139.  
519 doi:10.1046/j.1537-2995.2002.00186.x
- 520 17. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association  
521 of a reduction in cardiovascular events with blood donation. *Heart*. 1997;78(2):188-193.  
522 doi:10.1136/hrt.78.2.188
- 523 18. Peffer K, Den Heijer M, Holewijn S, De Graaf J, Swinkels DW, Verbeek ALM, Atsma F. The effect  
524 of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis:  
525 Subclinical Atherosclerosis in Blood Donors. *Transfusion*. 2013;53(7):1468-1474.  
526 doi:10.1111/j.1537-2995.2012.03916.x
- 527 19. Riško P, Pláteník J, Buchal R, Potočková J, Kraml PJ. Long-term donors versus non-donor men:  
528 Iron metabolism and the atherosclerotic process. *Atherosclerosis*. 2018;272:14-20.  
529 doi:10.1016/j.atherosclerosis.2018.03.009
- 530 20. Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron  
531 status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord*. 2009;9(1):34.  
532 doi:10.1186/1471-2261-9-34
- 533 21. Aščerić RR, Dimković NB, Trajković GŽ, Ristić BS, Janković AN, Durić PS, Ilijevski NS. Prevalence,  
534 clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a  
535 cross-sectional study. *BMC Nephrol*. 2019;20(1):281. doi:10.1186/s12882-019-1468-x
- 536 22. Lien CT, Lin KC, Tsai YF, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with progression  
537 of peripheral arterial disease in hemodialysis patients. *Clin Exp Nephrol*. 2015;19(5):947-952.  
538 doi:10.1007/s10157-014-1074-y
- 539 23. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK,  
540 Lavori PW. Reduction of Iron Stores and Cardiovascular Outcomes in Patients With Peripheral  
541 Arterial Disease: A Randomized Controlled Trial. *JAMA*. 2007;297(6):603.  
542 doi:10.1001/jama.297.6.603
- 543 24. Altamura S, Kopf S, Schmidt J, Müdder K, da Silva AR, Nawroth P, Muckenthaler MU.  
544 Uncoupled iron homeostasis in type 2 diabetes mellitus. *J Mol Med*. 2017;95(12):1387-1398.  
545 doi:10.1007/s00109-017-1596-3
- 546 25. Zoller H, Schaefer B, Vanclooster A, Griffiths B, Bardou-Jacquet E, Corradini E, Porto G, Ryan J,  
547 Cornberg M. EASL Clinical Practice Guidelines on haemochromatosis. *Journal of Hepatology*.  
548 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033
- 549 26. Qiu Z, Chen X, Geng T, Wan Z, Lu Q, Li L, Zhu K, Zhang X, Liu Y, Lin X, Chen L, Shan Z, Liu L, Pan  
550 A, Liu G. Associations of Serum Carotenoids With Risk of Cardiovascular Mortality Among  
551 Individuals With Type 2 Diabetes: Results From NHANES. *Diabetes Care*. 2022;45(6):1453-1461.  
552 doi:10.2337/dc21-2371
- 553 27. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U,  
554 Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley

- 555 M, Yeoman A. Guidelines on the management of abnormal liver blood tests. *Gut*. 2018;67(1):6-  
556 19. doi:10.1136/gutjnl-2017-314924
- 557 28. Ahlqvist E, Prasad RB, Groop L. Subtypes of Type 2 Diabetes Determined From Clinical  
558 Parameters. *Diabetes*. 2020;69(10):2086-2093. doi:10.2337/dbi20-0001
- 559 29. Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De  
560 Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther  
561 J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I, ESC Scientific  
562 Document Group, Widimsky P, Kolh P, Agewall S, Bueno H, Coca A, De Borst GJ, Delgado V, Dick  
563 F, Erol C, Ferrini M, Kakkos S, Katus HA, Knuuti J, Lindholt J, Mattle H, Pieniazek P, Piepoli MF,  
564 Scheinert D, Sievert H, Simpson I, Sulzenko J, Tamargo J, Tokgozoglu L, Torbicki A, Tsakountakis  
565 N, Tuñón J, De Ceniga MV, Windecker S, Zamorano JL, Windecker S, Aboyans V, Agewall S,  
566 Barbato E, Bueno H, Coca A, Collet JP, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli  
567 O, Hindricks G, Iung B, Juni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli  
568 MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Zelveian PH,  
569 Haumer M, Isachkin D, De Backer T, Dilic M, Petrov I, Kirhmajer MV, Karetova D, Prescott E,  
570 Soliman H, Paapstel A, Makinen K, Tosev S, Messas E, Pagava Z, Müller OJ, Naka KK, Járai Z, et  
571 al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in  
572 collaboration with the European Society for Vascular Surgery (ESVS). *European Heart Journal*.  
573 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095
- 574 30. R Core Team. R: A Language and Environment for Statistical Computing. Published online 2022.  
575 <https://www.R-project.org/>
- 576 31. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative.  
577 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)  
578 statement: guidelines for reporting observational studies. *Lancet*. 2007;370(9596):1453-1457.  
579 doi:10.1016/S0140-6736(07)61602-X
- 580 32. Allaire J. quarto: R Interface to “Quarto” Markdown Publishing System\_. R package version 1.2.  
581 Published online 2022. <https://CRAN.R-project.org/package=quarto>
- 582 33. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, Borges  
583 B. Shiny: Web Application Framework for R\_. R package version 1.7.4.1. Published online 2023.  
584 <https://CRAN.R-project.org/package=shiny>
- 585 34. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum Ferritin and C282Y  
586 Mutation of the Hemochromatosis Gene as Predictors of Asymptomatic Carotid  
587 Atherosclerosis in a Community Population. *Stroke*. 2000;31(12):3015-3020.  
588 doi:10.1161/01.STR.31.12.3015
- 589 35. Zhou J, Zhao R, Wang D, Gao Q, Zhao D, Ouyang B, Hao L, Peng X. Sex-Specific Association  
590 Between Iron Status and the Predicted 10-Year Risk for Atherosclerotic Cardiovascular Disease  
591 in Hypertensive Patients. *Biol Trace Elem Res*. 2022;200(11):4594-4607. doi:10.1007/s12011-  
592 021-03060-y
- 593 36. Ellervik C, Marott JL, Tybjærg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific  
594 mortality by moderately and markedly increased ferritin concentrations: general population  
595 study and metaanalysis. *Clin Chem*. 2014;60(11):1419-1428.  
596 doi:10.1373/clinchem.2014.229013



- 597 37. Kadoglou NPE, Biddulph JP, Rafnsson SB, Trivella M, Nihoyannopoulos P, Demakakos P. The  
598 association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The  
599 English longitudinal study of ageing. *PLoS One*. 2017;12(6):e0178994.  
600 doi:10.1371/journal.pone.0178994
- 601 38. Amar Z, Talpur AS, Zafar S, Memon A, Nazary K, Esmati S, Hashim S, Maqsood H, Hafizyar F,  
602 Kumar B. Comparison of Iron Profile in Patients With and Without Coronary Heart Disease.  
603 *Cureus*. Published online June 12, 2021. doi:10.7759/cureus.15613
- 604 39. Vega De Céniga M, Bravo E, Izagirre M, Casco C, Estallo L, Esteban M, Barba A. Anaemia, Iron  
605 and Vitamin Deficits in Patients with Peripheral Arterial Disease. *European Journal of Vascular  
606 and Endovascular Surgery*. 2011;41(6):828-830. doi:10.1016/j.ejvs.2011.01.017
- 607 40. Otaki Y, Watanabe T, Takahashi H, Sugai T, Yokoyama M, Tamura H, Kato S, Nishiyama S,  
608 Arimoto T, Shishido T, Watanabe M. Impact of Iron Deficiency on Peripheral Artery Disease  
609 After Endovascular Therapy. *Circ Rep*. 2019;1(4):187-195. doi:10.1253/circrep.CR-18-0029
- 610 41. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart  
611 disease. *N Engl J Med*. 1994;330(16):1119-1124. doi:10.1056/NEJM199404213301604
- 612 42. Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I. Which is the best way for estimating  
613 transferrin saturation? *Renal Failure*. 2010;32(8):1022-1023.  
614 doi:10.3109/0886022X.2010.502609
- 615 43. Vinchi F, Sparla R, Passos ST, Sharma R, Vance SZ, Zreid HS, Juaidi H, Manwani D, Yazdanbakhsh  
616 K, Nandi V, Silva AMN, Agarvas AR, Fibach E, Belcher JD, Vercellotti GM, Ghoti H, Muckenthaler  
617 MU. Vasculo-toxic and pro-inflammatory action of unbound haemoglobin, haem and iron in  
618 transfusion-dependent patients with haemolytic anaemias. *Br J Haematol*. 2021;193(3):637-  
619 658. doi:10.1111/bjh.17361
- 620 44. Friedrich N, Milman N, Völzke H, Linneberg A, Jørgensen T. Is serum ferritin within the  
621 reference range a risk predictor of cardiovascular disease? A population-based, long-term  
622 study comprising 2874 subjects. *Br J Nutr*. 2009;102(4):594-600.  
623 doi:10.1017/S000711450922085X
- 624 45. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD. Serum transferrin  
625 saturation, stroke incidence, and mortality in women and men. The NHANES I Epidemiologic  
626 Followup Study. National Health and Nutrition Examination Survey. *Am J Epidemiol*.  
627 1996;144(1):59-68. doi:10.1093/oxfordjournals.aje.a008855
- 628 46. DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR.  
629 Cytokine signatures in atherosclerotic claudicants. *Journal of Surgical Research*.  
630 2003;111(2):215-221. doi:10.1016/S0022-4804(03)00075-1
- 631 47. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hpcidin, a putative  
632 mediator of anemia of inflammation, is a type II acute-phase protein. *Blood*. 2003;101(7):2461-  
633 2463. doi:10.1182/blood-2002-10-3235
- 634 48. Guida C, Altamura S, Klein FA, Galy B, Boutros M, Ulmer AJ, Hentze MW, Muckenthaler MU. A  
635 novel inflammatory pathway mediating rapid hepcidin-independent hypoferremia. *Blood*.  
636 2015;125(14):2265-2275. doi:10.1182/blood-2014-08-595256

- 637 49. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases:  
638 from mechanisms to treatment options in anemia of inflammation. *Blood*. 2022;140(19):2011-  
639 2023. doi:10.1182/blood.2021013472
- 640 50. Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang D liang, Crooks DR, Sougrat R,  
641 Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is  
642 derived primarily from macrophages through a nonclassical secretory pathway. *Blood*.  
643 2010;116(9):1574-1584. doi:10.1182/blood-2009-11-253815
- 644 51. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on  
645 clinical outcomes in peripheral arterial disease. *American Heart Journal*. 2011;162(5):949-  
646 957.e1. doi:10.1016/j.ahj.2011.08.013
- 647 52. DePalma RG, Zacharski LR, Chow BK, Shamayeva G, Hayes VW. Reduction of iron stores and  
648 clinical outcomes in peripheral arterial disease: outcome comparisons in smokers and non-  
649 smokers. *Vascular*. 2013;21(4):233-241. doi:10.1177/1708538113478776
- 650

651

## 652 **Legends**

### 653 **Table 1. Demographics of HEIST-DiC participants**

654 The demographics of the HEIST-DiC participants classified by sex and the presence of PAD  
655 are shown in Table 1. For continuous variables, the summary data are shown as  
656 Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by  
657 the Wilcoxon rank sum test or Fisher's exact test and significant P-values are boldfaced.

658 BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein,  
659 HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular  
660 Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6,  
661 hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR:  
662 Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

663

### 664 **Table 2. Demographics of NHANES 1999-2004 participants**

665 The demographics of the NHANES 1999-2004 participants classified by sex and the  
666 presence of PAD are shown in Table 2. The N of participants shown are unweighted  
667 numbers. For continuous variables, the summary data are shown as Median (Interquartile  
668 Range), and for categorical variables as N (%)- survey weights were included in calculating  
669 the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact  
670 test and significant P-values are boldfaced.

671 BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein,  
672 HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated  
673 Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity,  
674 AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4: Fibrosis-4 index

675

676

### 677 **Figure 1. Odds Ratio plot of iron parameters with PAD: HEIST-DiC participants**

678 The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval)  
679 derived from the logistic regression analysis (sex-stratified) of each of the iron parameters  
680 with PAD.

681 Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes  
682 and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High  
683 sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

684

### 685 **Figure 2. The coefficient plot of iron parameters with ICAM-1: HEIST-DiC participants**

686 The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived  
687 from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.

688 Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes  
689 and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High  
690 sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

691

### 692 **Figure 3. The coefficient plot of iron parameters with VCAM-1: HEIST-DiC participants**

693 The plot shows a compilation of the estimate and 95% CI (95% Confidence Interval) derived  
694 from the linear regression analysis (sex-stratified) of each of the iron parameters with PAD.

695 Model 1: represents the univariate analysis. Model 2: adjusted for the presence of diabetes  
696 and hypertension. Model 3: adjusted for the presence of diabetes and hypertension, High  
697 sensitivity C-reactive protein, Urine Albumin-Creatinine Ratio, and Low-density Lipoprotein.

698

### 699 **Figure 4. The Odds Ratio plot of iron parameters with PAD: NHANES 1999-2004 participants**

700 The plot shows a compilation of the OR (odds ratio) and 95% CI (95% Confidence Interval)  
701 derived from the logistic regression analysis (sex-stratified) of each of the iron parameters  
702 with PAD.

703  
704 Model 1: represents the univariate analysis. Model 2: adjusted for age, ethnicity, BMI and  
705 smoking. Model 3: adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and

706 hypertension, FIB4 score, Urine Albumin-Creatinine Ratio, and C-reactive protein. Model 4:  
707 adjusted for age, ethnicity, BMI, smoking, the presence of diabetes and hypertension, FIB4  
708 score, Urine Albumin-Creatinine Ratio, C-reactive protein, LDL, antihyperlipidemic and  
709 antiplatelet medications, and HOMA2-IR.

710

#### 711 **Supplementary files**

712

##### 713 ***Supplementary Table 1. Model 4 Regression Summary NHANES 1999-2004.***

714 The table shows the regression results of the multivariate Model 4 analysis of iron  
715 biomarkers with PAD. The Odds ratio, 95% confidence interval, and p-value are shown in  
716 the table. The significant associations are highlighted in bold.

717

718

##### 719 ***Supplementary Table 2. Data fields and variables from NHANES 1999-2004.***

720 The table shows the variables and the corresponding codes used for accessing data from  
721 the NHANES. The hyperlinks to the procedure manuals and datafiles are also provided in  
722 the table.

723

##### 724 ***Supplementary Figure 1. The Odds Ratio plot of iron parameters with PAD: Sensitivity 725 analysis of NHANES 1999-2004 participants***

726

**Table 1. Baseline characteristics of HEIST-DiC participants**

Variable	Males (N=192)				Females (N=165)			
	N	No PAD N = 175	PAD N = 17	P-value	N	No PAD N = 159	PAD N = 6 <sup>1</sup>	P-value
<b>Age</b>	192	60 (11)	70 (8)	<b>&lt;0.001</b>	165	59 (11)	68 (7)	<b>0.025</b>
<b>BMI</b>	192	29.8 (5.1)	30.8 (6.0)	0.6	165	29.6 (6.3)	34.6 (5.1)	<b>0.036</b>
<b>Hypertension</b>	192			<b>0.09<sup>F</sup></b>				<b>0.028<sup>F</sup></b>
<b>No</b>	70	67 (38%)	3 (18%)		82	82 (52%)	0 (0%)	
<b>Yes</b>	122	108 (62%)	14 (82%)		165	77 (48%)	6 (100%)	
<b>Diabetes</b>	192			0.067 <sup>F</sup>	165			0.3 <sup>F</sup>
<b>No diabetes</b>	37	37 (21%)	0 (0%)		67	66 (42%)	1 (17%)	
<b>Prediabetes</b>	19	17 (9.7%)	2 (12%)		18	18 (11%)	0 (0%)	
<b>Diabetes</b>	136	121 (69%)	15 (88%)		80	75 (47%)	5 (83%)	
<b>Dietary management (=Yes)</b>	192	19 (11%)	3 (18%)	0.4 <sup>F</sup>	165	9 (5.7%)	1 (17%)	0.3 <sup>F</sup>
<b>Oral antidiabetic medications (=Yes)</b>	192	60 (34%)	7 (41%)	0.6 <sup>F</sup>	165	41 (26%)	2 (33%)	0.7 <sup>F</sup>
<b>Statins (=Yes)</b>	192	57 (33%)	6 (35%)	0.8 <sup>F</sup>	165	27 (17%)	2 (33%)	0.3 <sup>F</sup>
<b>Fasting blood glucose (mg/dL)</b>	192	135 (47)	175 (59)	<b>0.002</b>	165	121 (40)	157 (50)	0.067
<b>HbA1c (g/dL)</b>	192	6.78 (3.10)	7.40 (1.43)	<b>0.014</b>	165	6.25 (1.19)	7.13 (1.13)	0.056

Insulin	192	30 (17%)	5 (29%)	0.2	165	22 (14%)	2 (33%)	0.2
<b>Parameters of vascular function</b>								
Ankle-brachial index (Right)	191	1.11 (0.08)	0.84 (0.11)	<b>&lt;0.001</b>	164	1.09 (0.08)	0.81 (0.06)	<b>&lt;0.001</b>
Ankle-brachial index (Left)	191	1.12 (0.08)	0.90 (0.09)	<b>&lt;0.001</b>	161	1.09 (0.08)	0.93 (0.08)	<b>&lt;0.001</b>
Carotid intima-media thickness (mm)	176	0.63 (0.16)	0.71 (0.13)	<b>0.025</b>	161	0.59 (0.13)	0.83 (0.17)	<b>0.002</b>
Carotid-femoral Pulse Wave Velocity	185	8.79 (1.79)	10.43 (1.94)	<b>0.004</b>	163	8.43 (1.86)	11.80 (1.24)	<b>0.002</b>
ICAM1	162	287 (104)	363 (93)	<b>0.008</b>	134	308 (111)	269 (82)	0.6
VCAM1	162	869 (247)	1,035 (282)	<b>0.017</b>	134	828 (211)	743 (240)	0.8
<b>Other laboratory parameters</b>								
Triglycerides (mg/dL)	192	171 (166)	204 (100)	0.011	165	140 (93)	384 (567)	0.092
Cholesterol (mg/dL)	192	190 (47)	197 (59)	0.8	165	206 (42)	194 (41)	0.5
HDL (mg/dL)	192	49 (13)	43 (8)	0.067	165	61 (18)	55 (29)	0.3
LDL (mg/dL)	179	111 (42)	108 (37)	0.9	158	118 (35)	93 (23)	0.088
Hemoglobin (g/dL)	192	14.85 (1.06)	14.41 (1.26)	0.14	165	13.59 (0.93)	13.23 (1.30)	0.5
Mean Corpuscular	192	88.8 (4.6)	91.2 (5.7)	0.2	165	88.3 (4.2)	87.7 (5.0)	0.7

<b>Volume (fL)</b>								
<b>hsCRP</b>	184	2.11 (3.10)	3.68 (5.82)	0.3	159	3.5 (4.2)	7.9 (7.4)	0.083
<b>IL6</b>	150	3.16 (1.85)	4.44 (2.98)	0.010	128	3.42 (2.02)	4.50 (2.47)	0.3
<b>hsTNT</b>	174	10.8 (9.3)	13.7 (6.8)	0.033	147	7.1 (5.2)	11.6 (10.1)	0.2
<b>proBNP</b>	174	136 (365)	155 (149)	0.052	147	113 (197)	229 (149)	<b>0.008</b>
<b>eGFR (ml/min/1.73m<sup>2</sup>)</b>	192	91 (17)	76 (17)	0.002	165	91 (16)	67 (25)	<b>0.016</b>
<b>Urinary Albumin Creatinine Ratio (mg/g)</b>	188	81 (454)	130 (229)	0.001	164	29 (104)	72 (94)	<b>0.012</b>
<b>Iron-related parameters</b>								
<b>Iron</b>	192	17.8 (5.9)	18.1 (7.5)	0.7	165	16.9 (5.8)	18.0 (5.9)	0.6
<b>Ferritin</b>	192	189 (157)	232 (134)	0.10	165	99 (81)	198 (146)	<b>0.031</b>
<b>Transferrin</b>	189	2.41 (0.31)	2.41 (0.37)	0.6	161	2.47 (0.38)	2.57 (0.38)	0.6
<b>TSAT (%)</b>	189	27 (9)	23 (6)	0.2	159	25 (9)	22 (10)	0.5

**Table 1. Demographics of HEIST-DiC participants**

The demographics of the HEIST-DiC participants classified by sex and the presence of PAD are shown in Table 1. For continuous variables, the summary data are shown as Mean±Standard Deviation and for categorical variables as N (%). P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test<sup>F</sup> and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, ICAM1: Intercellular Adhesion Molecule 1, VCAM1: Vascular Cell Adhesion Molecule 1, hsCRP: High sensitivity C-reactive protein, IL6: Interleukin 6, hsTNT: High sensitivity Troponin T, proBNP: N-Terminal B-type Natriuretic Peptide, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation

**Table 2. Demographics of NHANES 1999-2004 participants**

Characteristic	Males				Females			
	Overall (N =5454)	No PAD (N =5067)	PAD (N =387)	P-value	Overall (N =3882)	No PAD (N =3519)	No PAD (N =363)	P-value
<b>Ethnicity</b>								
<b>Non-Hispanic White</b>	2,323 (79)	2,114 (79)	209 (84)	<b>0.003<sup>F</sup></b>	1,600 (75)	1,418 (74)	182 (78)	<b>0.005<sup>F</sup></b>
<b>Non-Hispanic Black</b>	742 (8.6)	677 (8.5)	65 (10)		647 (11)	573 (11)	74 (14)	
<b>Mexican-American</b>	871 (4.7)	812 (4.8)	59 (4.2)		676 (4.4)	621 (4.4)	55 (3.9)	
<b>Others</b>	252 (7.3)	244 (7.6)	8 (1.2)		261 (10)	245 (11)	16 (4.4)	
<b>Age (years)</b>	52 (45, 61)	51 (45, 60)	69 (61, 75)	<b>&lt;0.001</b>	52 (46, 67)	52 (45, 65)	71 (58, 79)	<b>&lt;0.001</b>
<b>BMI (kg/m<sup>2</sup>)</b>	27.9 (25.2, 30.8)	27.9 (25.2, 30.8)	28.0 (25.1, 32.0)	0.8	27 (24, 32)	27 (24, 32)	29 (25, 34)	<b>0.014</b>
<b>Diabetes (coded)</b>								
<b>No diabetes</b>	2,664 (74)	2,525 (62.6)	139 (3.4)	<b>&lt;0.001<sup>F</sup></b>	1,968 (72)	1,829 (59.4)	139 (4.5)	<b>&lt;0.001<sup>F</sup></b>
<b>Prediabetes</b>	643 (12)	548 (13.6)	95 (2.4)		568 (15)	484 (14.7)	84 (2.7)	
<b>Diabetes</b>	730 (14)	637 (15.8)	93 (2.3)		545 (13)	454 (15.7)	91 (3.0)	
<b>Hypertension (coded)</b>								
<b>No</b>	355 (22)	331 (19.9)	24 (1.5)	<b>0.026<sup>F</sup></b>	273 (21)	246 (17)	27 (1.9)	<b>0.6<sup>F</sup></b>
<b>Yes</b>	1,302 (78)	1,137 (68.6)	165 (9.9)		1,173 (79)	1,003 (69.4)	170 (11.8)	
<b>Smoking (coded)</b>								



<b>Nonsmoker</b>	1,488 (37)	1,419 (33.9)	69 (1.7)	<b>&lt;0.001<sup>F</sup></b>	1,899 (57)	1,729 (54.4)	170 (5.4)	0.2 <sup>F</sup>
<b>Former smoker</b>	1,776 (41)	1,602 (38.3)	174 (4.2)		792 (26)	692 (21.8)	100 (3.1)	
<b>Current smoker</b>	919 (22)	821 (19.6)	98 (2.3)		487 (17)	431 (13.6)	56 (1.8)	
<b>Alcohol drinker (coded)</b>								
<b>No</b>	282 (34)	263 (33.2)	19 (2.4)	0.6 <sup>F</sup>	723 (43)	632 (41.8)	91 (6.01)	>0.9 <sup>F</sup>
<b>Yes</b>	511 (66)	470 (59.3)	41 (5.2)		790 (57)	690 (45.6)	100 (6.6)	
<b>Physical activity (coded)</b>								
<b>Sedentary</b>	1,922 (42)	1,758 (42.9)	164 (4)	0.8 <sup>F</sup>	1,550 (43)	1,379 (45.2)	171 (5.6)	0.087 <sup>F</sup>
<b>Low to Moderate</b>	1,313 (38)	1,220 (29.8)	93 (2.3)		938 (37)	851 (27.9)	87 (2.9)	
<b>Vigorous</b>	863 (20)	793 (19.4)	70 (1.71)		564 (20)	524 (17.2)	40 (1.3)	
<b>Antihyperlipidemic medications (coded)</b>								
<b>No</b>	3,118 (82)	2,866 (76.4)	252 (6.7)	<b>&lt;0.001<sup>F</sup></b>	2,519 (87)	2,277 (77.9)	242 (8.3)	<b>&lt;0.001<sup>F</sup></b>
<b>Yes</b>	634 (18)	560 (14.9)	74 (1.97)		405 (13)	337 (11.5)	68 (2.3)	
<b>Antiplatelet medications (coded)</b>								
<b>No</b>	3,665 (98)	3,359 (89.5)	306 (8.2)	<b>&lt;0.001<sup>F</sup></b>	2,861 (98)	2,563 (68.3)	298 (7.9)	<b>0.006<sup>F</sup></b>
<b>Yes</b>	87 (1.6)	67 (1.8)	20 (0.5)		63 (1.7)	51 (1.4)	12 (0.3)	
<b>Ankle-brachial Index (Left)</b>	1.16 (1.10, 1.22)	1.17 (1.11, 1.22)	0.87 (0.79, 0.98)	<b>&lt;0.001</b>	1.11 (1.04, 1.19)	1.12 (1.06, 1.19)	0.88 (0.78, 0.96)	<b>&lt;0.001</b>
<b>Ankle-brachial Index (Right)</b>	1.16 (1.10, 1.22)	1.16 (1.11, 1.22)	0.87 (0.75, 0.96)	<b>&lt;0.001</b>	1.10 (1.03, 1.18)	1.11 (1.05, 1.19)	0.86 (0.77, 0.90)	<b>&lt;0.001</b>

<b>Albumin (g/L)</b>	44.0 (42.0, 46.0)	44.0 (42.0, 46.0)	43.0 (41.0, 45.0)	<b>&lt;0.001</b>	43.0 (41.0, 44.4)	43.0 (41.0, 45.0)	42.0 (39.0, 44.0)	<b>0.003</b>
<b>AST (U/L)</b>	26 (21, 33)	26 (21, 34)	22 (18, 27)	<b>&lt;0.001</b>	19 (16, 25)	19 (16, 25)	20 (16, 25)	0.9
<b>ALT (U/L)</b>	24 (21, 29)	24 (21, 29)	23 (20, 29)	0.2	21 (18, 25)	21 (18, 25)	22 (19, 26)	0.087
<b>Blood urea nitrogen (mmol/L)</b>	5.36 (4.28, 6.10)	5.00 (4.28, 6.10)	6.07 (4.64, 7.14)	<b>&lt;0.001</b>	4.60 (3.57, 5.71)	4.60 (3.57, 5.71)	5.00 (3.90, 7.14)	<b>0.010</b>
<b>Creatinine (μmol/L)</b>	88 (71, 97)	88 (71, 97)	88 (80, 115)	<b>0.002</b>	62 (62, 80)	62 (53, 71)	80 (62, 88)	<b>&lt;0.001</b>
<b>Total Cholesterol (mmol/L)</b>	5.22 (4.55, 5.89)	5.22 (4.55, 5.90)	4.86 (4.04, 5.58)	<b>0.003</b>	5.33 (4.71, 6.03)	5.33 (4.71, 6.03)	5.38 (4.81, 5.95)	0.7
<b>Triacylglycerols (mmol/L)</b>	1.49 (1.01, 2.24)	1.49 (1.01, 2.24)	1.47 (0.97, 2.37)	0.8	1.22 (0.81, 1.82)	1.20 (0.80, 1.78)	1.59 (1.09, 2.45)	<b>&lt;0.001</b>
<b>LDL (mmol/L)</b>	3.16 (2.61, 3.75)	3.18 (2.61, 3.78)	2.85 (2.17, 3.41)	<b>0.025</b>	3.13 (2.59, 3.72)	3.13 (2.59, 3.72)	3.05 (2.50, 3.62)	0.8
<b>HDL (mmol/L)</b>	1.14 (0.98, 1.39)	1.14 (0.98, 1.40)	1.16 (0.96, 1.34)	0.6	1.45 (1.19, 1.73)	1.45 (1.22, 1.73)	1.32 (1.11, 1.55)	<b>0.001</b>
<b>Fasting plasma glucose (mmol/L)</b>	5.62 (5.24, 6.21)	5.61 (5.25, 6.16)	5.89 (5.18, 6.73)	0.5	5.29 (4.97, 5.79)	5.28 (4.95, 5.74)	5.81 (5.36, 6.93)	<b>&lt;0.001</b>
<b>Insulin (pmol/L)</b>	57 (38, 91)	57 (38, 90)	70 (41, 108)	0.14	46 (32, 79)	46 (31, 74)	106 (47, 190)	<b>&lt;0.001</b>
<b>CRP (mg/dL)</b>	0.17 (0.08, 0.35)	0.17 (0.08, 0.35)	0.26 (0.17, 0.43)	<b>&lt;0.001</b>	0.25 (0.10, 0.58)	0.25 (0.10, 0.57)	0.33 (0.15, 0.90)	<b>0.009</b>
<b>Hemoglobin (g/dL)</b>	15.20 (14.60, 16.00)	15.20 (14.70, 16.00)	14.90 (14.10, 15.60)	<b>&lt;0.001</b>	13.80 (13.10, 14.50)	13.90 (13.10, 14.50)	13.80 (12.90, 14.80)	>0.9


<b>FIB4 Score</b>	1.15 (0.91, 1.51)	1.14 (0.90, 1.50)	1.35 (1.10, 1.67)	<b>&lt;0.001</b>	0.87 (0.64, 1.17)	0.84 (0.63, 1.15)	1.11 (0.83, 1.44)	<b>&lt;0.001</b>
<b>Albumin-creatinine ratio (µg/mg)</b>	0.60 (0.41, 1.06)	0.58 (0.40, 1.00)	1.13 (0.65, 2.78)	<b>&lt;0.001</b>	0.80 (0.54, 1.51)	0.77 (0.53, 1.40)	1.30 (0.70, 2.59)	<b>&lt;0.001</b>
<b>Iron (µg/dL)</b>	91 (72, 115)	92 (73, 115)	80 (64, 108)	<b>&lt;0.001</b>	78 (60, 99)	79 (60, 99)	75 (57, 96)	0.2
<b>Ferritin (µg/dL)</b>	146 (96, 259)	146 (97, 258)	127 (81, 262)	0.5	64 (32, 109)	62 (31, 106)	87 (56, 252)	<b>&lt;0.001</b>
<b>TSAT (%)</b>	26 (21, 33)	26 (21, 33)	24 (17, 30)	<b>0.021</b>	22 (16, 29)	22 (16, 29)	20 (16, 30)	0.5
<b>TIBC (µmol/L)</b>	63 (57, 70)	63 (57, 70)	65 (58, 72)	0.5	63 (58, 71)	64 (58, 71)	60 (54, 68)	<b>0.001</b>

**Table 2. Demographics of NHANES 1999-2004 participants**


The demographics of the NHANES 1999-2004 participants classified by sex and the presence of PAD are shown in Table 2. The N of participants shown are unweighted numbers. For continuous variables, the summary data are shown as Median (Interquartile Range), and for categorical variables as N (%)-survey weights were included in calculating the summary data. P-values as calculated by the Wilcoxon rank sum test or Fisher's exact test<sup>F</sup> and significant P-values are boldfaced.

BMI: Body Mass Index, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, HbA1c: Glycated hemoglobin, CRP: High sensitivity C-reactive protein, eGFR: Estimated Glomerular Filtration Rate, TSAT: Transferrin Saturation, TIBC: Total Iron Binding Capacity, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, FIB4 Score: Fibrosis-4 index Score


# Serum iron indices vs PAD: HEIST-DiC



# Serum iron indices vs ICAM1: HEIST-DiC



# Serum iron indices vs VCAM1: HEIST-DiC



# Iron parameters vs PAD: NHANES

